June 10, 2019
Otsuka Pharmaceutical and Taiho Pharmaceutical said on June 7 that the anticancer drug candidates guadecitabine and ASTX727, which are developed by an Otsuka subsidiary, will be marketed by Taiho’s subsidiaries in North America. The two agents, which are developed by...read more